High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease

Blood

Volumn 116, Issue 17, 2010, Pages 3180-3184

  Berentsen, Sigbjørn ^a   Randen, Ulla ^b   Vågan, Anne Marita ^c   Hjorth Hansen, Henrik ^d,e   Vik, Anders ^f   Dalgaard, Jakob ^g   Jacobsen, Eva Marie ^b,h   Thoresen, Aud S ⁱ   Beiske, Klaus ^b   Tjønnfjord, Geir E ^b,h  

^a HAUGESUND HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Ålesund Hospital   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^g Hospital of Buskerud   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ INNLANDET HOSPITAL TRUST   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; FLUDARABINE PHOSPHATE; HEMOGLOBIN; RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COLD AGGLUTININ SYNDROME; COMORBIDITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTICENTER STUDY; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 78049356387     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-288647     Document Type: Article

References (29)

1. Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007;12(5):361-370. (Pubitemid 47487842)
2. Harboe M, van Furth R, Schubothe H, et al. Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand J Haematol. 1965;2(3):259-266.
3. Pascual V, Victor K, Spellerberg M, et al. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol. 1992;149(7):2337-2344.
4. Berentsen S, Bø K, Shammas FV, et al. Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105(5):354-362.
5. Ulvestad E, Berentsen S, Bø K, et al. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol. 1999;63(4):259-266.
6. Dacie J. Treatment and prognosis of coldantibody AIHA. In: Dacie J, ed. The Haemolytic Anaemias, Vol. 3. London: Churchill Livingstone, 1992:502-508.
7. Hillen HF, Bakker SJ. Failure of interferonalpha- 2b therapy in chronic cold agglutinin disease. Eur J Haematol. 1994;53(4):242-243.
8. Berentsen S, Tjønnfjord GE, Shammas FV, et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol. 2000;65(1):88-90.
9. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460-466.
10. Gertz MA. Cold hemolytic syndrome. Hematology Am Soc Hematol Educ Program. 2006;19-23.
11. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925-2928.
12. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47(2):253-260.
13. Silverman GJ. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci. 2007;12:2194-2206.
14. Berentsen S. Rituximab for the treatment of autoimmune cytopenias. Haematologica. 2007;92(12):1589-1596.
15. Jacobs A. Cold agglutinin hemolysis responding to fludarabine therapy. Am J Hematol. 1996;53(4):279-280. (Pubitemid 26419723)
16. Leblond V, Choquet S. Fludarabine in Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):239-242.
17. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood. 2006;107(9):3442-3446.
18. Berentsen S. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):110-112.
19. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23(4):694-704.
20. Jaffe ES, Harris NL, Stein H, Vardiman JW, ed. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. WHO classification of tumours, Vol. 3. Lyon: IARC Press; 2001.
21. Isaksson E, Björkholm M, Holm G, et al. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Br J Haematol. 1996;92(1):71-76.
22. Ulvestad E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur J Haematol. 1998;60(2):93-100.
23. Ulvestad E, Berentsen S, Mollnes TE. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol. 54(1-2):239-242, 2001.
24. Berentsen S, Ulvestad E, Tjønnfjord GE. B-lymphocytes as targets for therapy in chronic cold agglutinin disease. Cardiovasc Hematol Disord Drug Targets. 2007;7(3):219-227.
25. Beutler E, Sipe J, Romine J, et al. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol. 1996;33(1 Suppl 1):45-52. (Pubitemid 26061753)
26. Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol. 2008;35(7):1245-1255.
27. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20(4):444-449.
28. Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus benefit in the treatment of Waldenstrom's macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009;9(1):71-73.
29. Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92(12):1695-1698.